Post by JHam on Aug 10, 2015 18:52:20 GMT
Including the RPE patent:
www.businesswire.com/news/home/20150810005426/en/BioTime-Announces-Issuance-27-Patents-Protecting-Stem#.VcjveRjXeK1
United States patent 8,956,866 – “Retinal Pigment Epithelial Cells Differentiated from Embryonic Stem Cells with Nicotinamide and Activin A” discloses methods useful in the manufacture retinal pigment epithelial (RPE) cells such as OpRegen®, a product in clinical development by BioTime’s subsidiary, Cell Cure Neurosciences, Inc. for the treatment of the dry form of age-related macular degeneration.
www.businesswire.com/news/home/20150810005426/en/BioTime-Announces-Issuance-27-Patents-Protecting-Stem#.VcjveRjXeK1
United States patent 8,956,866 – “Retinal Pigment Epithelial Cells Differentiated from Embryonic Stem Cells with Nicotinamide and Activin A” discloses methods useful in the manufacture retinal pigment epithelial (RPE) cells such as OpRegen®, a product in clinical development by BioTime’s subsidiary, Cell Cure Neurosciences, Inc. for the treatment of the dry form of age-related macular degeneration.